# Vericel Corp: financial statements, quarterly

VCEL · Nasdaq · CIK 887359 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/vcel.md) · [Financials](/companies/vcel/financials.md) · [Filings](/companies/vcel/filings.md) · [Insiders](/companies/vcel/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/vcel/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [45.6](/filings/0001628280-24-046015.md) | [65.0 d](/filings/0001628280-26-012013.md) | [51.3](/filings/0001628280-25-023496.md) | [52.7](/filings/0001628280-25-036859.md) | [57.9](/filings/0001628280-25-049902.md) | [75.4 d](/filings/0001628280-26-012013.md) | [52.6](/filings/0001628280-26-031742.md) | [63.2](/filings/0001628280-26-050836.md) | [67.5](/filings/0001628280-25-049902.md) | [92.9 d](/filings/0001628280-26-012013.md) | [68.4](/filings/0001628280-26-031742.md) | [77.5](/filings/0001628280-26-050836.md) |
| Cost of revenue | $m | [15.0](/filings/0001628280-24-046015.md) | [16.5 d](/filings/0001628280-26-012013.md) | [15.9](/filings/0001628280-25-023496.md) | [16.1](/filings/0001628280-25-036859.md) | [16.3](/filings/0001628280-25-049902.md) | [16.9 d](/filings/0001628280-26-012013.md) | [16.3](/filings/0001628280-26-031742.md) | [16.6](/filings/0001628280-26-050836.md) | [17.9](/filings/0001628280-25-049902.md) | [19.8 d](/filings/0001628280-26-012013.md) | [19.2](/filings/0001628280-26-031742.md) | [21.1](/filings/0001628280-26-050836.md) |
| Gross profit | $m | [30.6](/filings/0001628280-24-046015.md) | [48.5 d](/filings/0001628280-26-012013.md) | [35.4](/filings/0001628280-25-023496.md) | [36.6](/filings/0001628280-25-036859.md) | [41.7](/filings/0001628280-25-049902.md) | [58.5 d](/filings/0001628280-26-012013.md) | [36.3](/filings/0001628280-26-031742.md) | [46.6](/filings/0001628280-26-050836.md) | [49.6](/filings/0001628280-25-049902.md) | [73.1 d](/filings/0001628280-26-012013.md) | [49.3](/filings/0001628280-26-031742.md) | [56.4](/filings/0001628280-26-050836.md) |
| Research and development | $m | [5.7](/filings/0001628280-24-046015.md) | [4.9 d](/filings/0001628280-26-012013.md) | [6.4](/filings/0001628280-25-023496.md) | [7.4](/filings/0001628280-25-036859.md) | [6.1](/filings/0001628280-25-049902.md) | [4.9 d](/filings/0001628280-26-012013.md) | [7.3](/filings/0001628280-26-031742.md) | [6.7](/filings/0001628280-26-050836.md) | [6.3](/filings/0001628280-25-049902.md) | [7.3 d](/filings/0001628280-26-012013.md) | [8.1](/filings/0001628280-26-031742.md) | [7.5](/filings/0001628280-26-050836.md) |
| Selling, general and administrative | $m | [30.0](/filings/0001628280-24-046015.md) | [30.9 d](/filings/0001628280-26-012013.md) | [34.4](/filings/0001628280-25-023496.md) | [35.3](/filings/0001628280-25-036859.md) | [38.0](/filings/0001628280-25-049902.md) | [35.1 d](/filings/0001628280-26-012013.md) | [41.8](/filings/0001628280-26-031742.md) | [41.9](/filings/0001628280-26-050836.md) | [39.8](/filings/0001628280-25-049902.md) | [43.5 d](/filings/0001628280-26-012013.md) | [49.2](/filings/0001628280-26-031742.md) | [48.5](/filings/0001628280-26-050836.md) |
| Operating income | $m | [(5.1)](/filings/0001628280-24-046015.md) | [12.7 d](/filings/0001628280-26-012013.md) | [(5.5)](/filings/0001628280-25-023496.md) | [(6.0)](/filings/0001628280-25-036859.md) | [(2.5)](/filings/0001628280-25-049902.md) | [18.5 d](/filings/0001628280-26-012013.md) | [(12.8)](/filings/0001628280-26-031742.md) | [(2.0)](/filings/0001628280-26-050836.md) | [3.5](/filings/0001628280-25-049902.md) | [22.4 d](/filings/0001628280-26-012013.md) | [(8.1)](/filings/0001628280-26-031742.md) | [0.4](/filings/0001628280-26-050836.md) |
| Interest expense | $m | [0.2](/filings/0001628280-23-037583.md) | [0.2 d](/filings/0001628280-24-007824.md) | [0.2](/filings/0001628280-24-021399.md) | [0.2](/filings/0001628280-25-036859.md) | [0.2](/filings/0001628280-25-049902.md) | [0.2 d](/filings/0001628280-26-012013.md) | [0.2](/filings/0001628280-26-031742.md) | [0.2](/filings/0001628280-26-050836.md) | [0.2](/filings/0001628280-25-049902.md) | [0.2 d](/filings/0001628280-26-012013.md) | [0.2](/filings/0001628280-26-031742.md) | [0.2](/filings/0001628280-26-050836.md) |
| Income tax | $m | [(0.3)](/filings/0001628280-24-046015.md) | [1.1 d](/filings/0001628280-26-012013.md) | not reported | not reported | [0.0](/filings/0001628280-24-046015.md) | [0.1 d](/filings/0001628280-26-012013.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(3.7)](/filings/0001628280-24-046015.md) | [13.0 d](/filings/0001628280-26-012013.md) | [(3.9)](/filings/0001628280-25-049902.md) | [(4.7)](/filings/0001628280-25-049902.md) | [(0.9)](/filings/0001628280-25-049902.md) | [19.8 d](/filings/0001628280-26-012013.md) | [(11.2)](/filings/0001628280-26-050836.md) | [(0.6)](/filings/0001628280-26-050836.md) | [5.1](/filings/0001628280-25-049902.md) | [23.2 d](/filings/0001628280-26-012013.md) | [(6.3)](/filings/0001628280-26-050836.md) | [2.2](/filings/0001628280-26-050836.md) |
| Diluted EPS | $ per share | [(0.08)](/filings/0001628280-24-046015.md) | not reported | [(0.08)](/filings/0001628280-25-023496.md) | [(0.10)](/filings/0001628280-25-036859.md) | [(0.02)](/filings/0001628280-25-049902.md) | not reported | [(0.23)](/filings/0001628280-26-031742.md) | [(0.01)](/filings/0001628280-26-050836.md) | [0.10](/filings/0001628280-25-049902.md) | not reported | [(0.12)](/filings/0001628280-26-031742.md) | [0.04](/filings/0001628280-26-050836.md) |
| Basic EPS | $ per share | [(0.08)](/filings/0001628280-24-046015.md) | not reported | [(0.08)](/filings/0001628280-25-023496.md) | [(0.10)](/filings/0001628280-25-036859.md) | [(0.02)](/filings/0001628280-25-049902.md) | not reported | [(0.23)](/filings/0001628280-26-031742.md) | [(0.01)](/filings/0001628280-26-050836.md) | [0.10](/filings/0001628280-25-049902.md) | not reported | [(0.12)](/filings/0001628280-26-031742.md) | [0.04](/filings/0001628280-26-050836.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [60.5](/filings/0001628280-24-046015.md) | [69.1](/filings/0001628280-26-012013.md) | [62.9](/filings/0001628280-25-023496.md) | [50.3](/filings/0001628280-25-036859.md) | [53.7](/filings/0001628280-25-049902.md) | [74.5](/filings/0001628280-26-012013.md) | [73.5](/filings/0001628280-26-031742.md) | [80.5](/filings/0001628280-25-036859.md) | [100](/filings/0001628280-25-049902.md) | [100](/filings/0001628280-26-050836.md) | [109](/filings/0001628280-26-031742.md) | [125](/filings/0001628280-26-050836.md) |
| Current assets | $m | [186](/filings/0001628280-23-037583.md) | [206](/filings/0001628280-25-008447.md) | [190](/filings/0001628280-24-021399.md) | [197](/filings/0001628280-24-033905.md) | [191](/filings/0001628280-24-046015.md) | [213](/filings/0001628280-26-012013.md) | [198](/filings/0001628280-25-023496.md) | [205](/filings/0001628280-25-036859.md) | [222](/filings/0001628280-25-049902.md) | [247](/filings/0001628280-26-050836.md) | [244](/filings/0001628280-26-031742.md) | [265](/filings/0001628280-26-050836.md) |
| Total assets | $m | [318](/filings/0001628280-23-037583.md) | [354](/filings/0001628280-25-008447.md) | [357](/filings/0001628280-24-021399.md) | [377](/filings/0001628280-24-033905.md) | [390](/filings/0001628280-24-046015.md) | [433](/filings/0001628280-26-012013.md) | [425](/filings/0001628280-25-023496.md) | [436](/filings/0001628280-25-036859.md) | [453](/filings/0001628280-25-049902.md) | [488](/filings/0001628280-26-050836.md) | [486](/filings/0001628280-26-031742.md) | [503](/filings/0001628280-26-050836.md) |
| Current liabilities | $m | [35.9](/filings/0001628280-23-037583.md) | [45.7](/filings/0001628280-25-008447.md) | [36.5](/filings/0001628280-24-021399.md) | [43.9](/filings/0001628280-24-033905.md) | [41.3](/filings/0001628280-24-046015.md) | [50.3](/filings/0001628280-26-012013.md) | [39.4](/filings/0001628280-25-023496.md) | [41.1](/filings/0001628280-25-036859.md) | [45.6](/filings/0001628280-25-049902.md) | [49.1](/filings/0001628280-26-050836.md) | [47.2](/filings/0001628280-26-031742.md) | [52.5](/filings/0001628280-26-050836.md) |
| Total liabilities | $m | [114](/filings/0001628280-23-037583.md) | [128](/filings/0001628280-25-008447.md) | [123](/filings/0001628280-24-021399.md) | [134](/filings/0001628280-24-033905.md) | [133](/filings/0001628280-24-046015.md) | [141](/filings/0001628280-26-012013.md) | [129](/filings/0001628280-25-023496.md) | [129](/filings/0001628280-25-036859.md) | [131](/filings/0001628280-25-049902.md) | [133](/filings/0001628280-26-050836.md) | [129](/filings/0001628280-26-031742.md) | [133](/filings/0001628280-26-050836.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [204](/filings/0001628280-24-046015.md) | [226](/filings/0001628280-26-012013.md) | [234](/filings/0001628280-25-049902.md) | [243](/filings/0001628280-25-049902.md) | [257](/filings/0001628280-25-049902.md) | [292](/filings/0001628280-26-050836.md) | [295](/filings/0001628280-26-050836.md) | [307](/filings/0001628280-26-050836.md) | [322](/filings/0001628280-25-049902.md) | [355](/filings/0001628280-26-050836.md) | [356](/filings/0001628280-26-050836.md) | [370](/filings/0001628280-26-050836.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [7.2 d](/filings/0001628280-24-046015.md) | [10.1 d](/filings/0001628280-26-012013.md) | [7.2](/filings/0001628280-25-023496.md) | [18.5 d](/filings/0001628280-25-036859.md) | [10.2 d](/filings/0001628280-25-049902.md) | [22.2 d](/filings/0001628280-26-012013.md) | [6.6](/filings/0001628280-26-031742.md) | [8.2 d](/filings/0001628280-26-050836.md) | [22.1 d](/filings/0001628280-25-049902.md) | [15.0 d](/filings/0001628280-26-012013.md) | [16.4](/filings/0001628280-26-031742.md) | [16.2 d](/filings/0001628280-26-050836.md) |
| Capital expenditure | $m | [6.6 d](/filings/0001628280-24-046015.md) | [7.8 d](/filings/0001628280-26-012013.md) | [14.0](/filings/0001628280-25-023496.md) | [16.8 d](/filings/0001628280-25-036859.md) | [19.4 d](/filings/0001628280-25-049902.md) | [13.8 d](/filings/0001628280-26-012013.md) | [14.2](/filings/0001628280-26-031742.md) | [8.1 d](/filings/0001628280-26-050836.md) | [2.6 d](/filings/0001628280-25-049902.md) | [2.2 d](/filings/0001628280-26-012013.md) | [1.3](/filings/0001628280-26-031742.md) | [1.9 d](/filings/0001628280-26-050836.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [47.2](/filings/0001628280-23-037583.md) | [47.4](/filings/0001628280-24-021399.md) | [47.6](/filings/0001628280-24-033905.md) | [47.6](/filings/0001628280-24-046015.md) | [48.1](/filings/0001628280-25-023496.md) | [48.7](/filings/0001628280-25-036859.md) | [49.1](/filings/0001628280-25-049902.md) | [49.9](/filings/0001628280-26-031742.md) | [50.4](/filings/0001628280-26-050836.md) | [51.9](/filings/0001628280-25-049902.md) | [50.8](/filings/0001628280-26-031742.md) | [52.3](/filings/0001628280-26-050836.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 51,206,614 at 2026-07-24, from the cover of the [10-Q filed 2026-07-30](/filings/0001628280-26-050836.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:27 ET. No prices; not investment advice.